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Data from epidemiological studies suggest that prenatal exposure to bacterial and
viral infection is an important environmental risk factor for schizophrenia. The maternal
immune activation (MIA) animal model is used to study how an insult directed at
the maternal host can have adverse effects on the fetus, leading to behavioral and
neurochemical changes later in life. We evaluated whether the administration of LPS
to rat dams during late pregnancy affects astroglial markers (S100B and GFAP) of the
offspring in later life. The frontal cortex and hippocampus were compared in male and
female offspring on postnatal days (PND) 30 and 60. The S100B protein exhibited
an age-dependent pattern of expression, being increased in the frontal cortex and
hippocampus of the MIA group at PND 60, while at PND 30, male rats presented
increased S100B levels only in the frontal cortex. Considering that S100B secretion is
reduced by elevation of glutamate levels, we may hypothesize that this early increment
in frontal cortex tissue of males is associated with elevated extracellular levels of
glutamate and glutamatergic hypofunction, an alteration commonly associated with
SCZ pathology. Moreover, we also found augmented GFAP in the frontal cortex of the
LPS group at PND 30, but not in the hippocampus. Taken together data indicate that
astroglial changes induced by MIA are dependent on sex and brain region and that
these changes could reflect astroglial dysfunction. Such alterations may contribute to
our understanding of the abnormal neuronal connectivity and developmental aspects of
SCZ and other psychiatric disorders.
Keywords: animal model, astrogliosis, GFAP, lipopolysaccharide, schizophrenia, S100B
INTRODUCTION
Schizophrenia (SCZ) is a chronic and debilitating illness that affects about 1% of
the world population, with the onset of the manifestation occurring typically in
late adolescence or in early adulthood (Monji et al., 2013). The incidence of SCZ
is significantly higher in men than in women (male: female ratio = 1.4) (Aleman
et al., 2003; McGrath et al., 2008). Nevertheless, the etiology of SCZ remains unclear,
although numerous findings indicate that neurodevelopmental factors contribute to its
Abbreviations: CNS, central nervous system; ELISA, enzyme-linked immunosorbent assay; GFAP, glial fibrillary acidic
protein; GSH, glutathione; IL-6, interleukin-6; LPS, lipopolysaccharide; MIA, maternal immune activation; NeuN, neuronal
nuclei; PND, postnatal day; ROS, reactive oxygen species.
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pathophysiology (Murray et al., 1992; Knuesel et al., 2014).
Among these factors are included prenatal exposure to infection
agents such as viruses (Kneeland and Fatemi, 2012) and gram-
negative bacteria (Babulas et al., 2006; Sørensen et al., 2009;
Khandaker et al., 2012).
The MIA animal model is used to study how an insult directed
at the maternal host can have adverse effects on the fetus,
leading to behavioral and neurochemistry changes later in life,
specifically within abnormal exploration and social behaviors,
cytokine levels and gene regulation (Ashdown et al., 2006;
Fatemi et al., 2008; Meyer et al., 2009). Interestingly, prenatal
exposure to the viral mimetic polyinosinic-polycytidylic acid
changed behavioral flexibility of offspring rats, in a sex-dependent
manner (Zhang et al., 2012). Systemic administration of the
bacterial endotoxin, LPS, is a widely used and accepted MIA
model that emulates immune activation and subsequent release
of immunoregulatory, cytotoxic and inflammatory cytokines
secondary to gram-negative bacterial infections (Borrell et al.,
2002). Furthermore, inflammatory signals have been described in
the hippocampus and cerebral cortex in postmortem studies of
SCZ patients and MIA models (Beumer et al., 2012).
Changes in glial cells seem to be closely related to the
pathology of SCZ (Cotter et al., 2001; Bernstein et al., 2009;
Beumer et al., 2012). Astrocytes, the most abundant glial
cells, are involved, together with microglia, in brain immune
activation, as well as antioxidant defenses and glutamatergic
neurotransmission (Takuma et al., 2004; Liu et al., 2011). S100B, a
protein mainly expressed and secreted by astrocytes in the CNS,
has been proposed as a marker of brain damage (Marchi et al.,
2004; Gonçalves et al., 2008; Koh and Lee, 2014) and several
studies have suggested that S100B is altered in neurological and
psychiatric disorders (Ashraf et al., 1999; Lara et al., 2001; Steiner
et al., 2011). Corroborating the idea of the neuroinflammatory
basis of SCZ, and the involvement of the S100B protein in its
pathogenesis, we recently showed that cerebrospinal fluid (CSF)
S100B is increased by intracerebroventricular or intraperitoneal
LPS administration (Guerra et al., 2011). Furthermore we
observed that S100B secretion stimulated by cytokines in vitro is
prevented by antipsychotics (de Souza et al., 2013).
Brain inflammation involving astrogliosis (characterized by
over expression of GFAP and/or astrocyte hypertrophy) has
been observed in the offspring of models of MIA, in IL-6
or LPS-treated mothers (Samuelsson et al., 2006; Hao et al.,
2010). However, the role of GFAP in SCZ is controversial; some
studies have found no changes or decreased GFAP content
in the cortex and cerebellum of schizophrenic patients (Falkai
et al., 1999; Rajkowska et al., 2002). On the other hand, there
is evidence that this protein might be significantly augmented
in demented schizophrenic patients, when compared to non-
demented patients (Arnold et al., 1996).
Additionally, studies suggest that the altered regulation
of fundamental mechanisms of anti-oxidant defense, where
astrocytes are key elements (Takuma et al., 2004), may contribute
to the pathogenesis of SCZ and related disorders (Floyd, 1999;
Chauhan and Chauhan, 2006; Boskovic et al., 2011). In fact,
analyses of the molecular mechanisms underlying oxidative
stress suggest that cognitive dysfunction may be associated
with an imbalance in the generation and clearance of ROS
(Bitanihirwe and Woo, 2011) and MIA models support the role
of oxidative/nitrosative stress in SCZ (Venkatasubramanian and
Debnath, 2013)
In this study, we evaluated whether the administration of LPS
in rat dams during late pregnancy affects the main astroglial
markers, S100B and GFAP, in the frontal cerebral cortex and
hippocampus of the dams’ offspring during later life. S100B levels
were also investigated in CSF and serum. We compared the
offspring at 30 and 60 days to evaluate the possible differences
between juvenile and adult rats and also investigated the existence
of differences between male and female offspring. We also
investigated the oxidative/nitrosative stress parameters, NO and
GSH contents, in this model.
MATERIALS AND METHODS
Animals
Female Wistar rats from our breeding colony (Department of
Biochemistry, UFRGS, Porto Alegre, Brazil), weighing 216–263 g
each, were used, and maintained under controlled light and
environmental conditions (12 h light/12 h dark cycle at a constant
temperature of 22 ± 1◦C), with free access to commercial chow
and water. The fertility cycle of the rats was controlled, and, when
on proestrus, they were mated overnight. In the morning, vaginal
secretion was collected for analysis. If spermatozoa were found in
the morning, the day was designated as the first day of pregnancy.
All animal experiments were carried out in accordance with
the National Institute of Health Guide for the Care and Use
of Laboratory Animals (NIH Publications No. 80-23) revised in
1996 and followed the regulations of the local animal housing
authorities.
The study has been approved by the Comite de Etica no Uso
de Animais (CEUA), UFRGS, number 18672.
LPS Administration to Pregnant Rats
For gestational LPS treatment, timed pregnant Wistar rats were
injected on days 18 and 19 of pregnancy, as follows: six pregnant
rats were injected intraperitoneally with 500 μg/kg LPS (from
Escherichia coli, serotype 055:B5, Sigma) and five were injected
with a corresponding volume of sterile saline (control), once
daily. Females were kept separate and with free access to their
own litters. Rats from both groups (control and LPS) were born
healthy and the numbers of offspring were normal. The offspring
rats were weaned at 21 days old and were housed separately
according to sex. The experiments were performed using male
and female rats from each litter. Rats had free access to food and
water. All the experiments were performed between 12:00 h and
17:00 h. In order to analyze the differences between young and
adult rats, experiments were performed at PND 30 and PND 60
(Cai et al., 2000).
Obtaining CSF, Serum and Hippocampal
Samples
Animals were anesthetized with ketamine/xylazine (75 and
10 mg/kg, respectively, i.p.) and then positioned in a stereotaxic
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holder; CSF was obtained by cisterna magna puncture using
an insulin syringe (27 gage × 1/2 inch length). The blood
samples were collected by careful intracardiac puncture, using a
5-mL non-heparinized syringe to obtain 3 mL of blood. Blood
samples were incubated at room temperature (25◦C) for 5 min
and centrifuged at 3200 rpm for 5 min to obtain serum. CSF
and serum were frozen (−20◦C) until further analysis, at most
for 2 weeks. The animals were killed by decapitation, and
the brains were removed and placed in cold saline medium
with the following composition (in mM): 120 NaCl; 2 KCl;
1 CaCl2; 1 MgSO4; 25 HEPES; 1 KH2PO4 and 10 glucose,
adjusted to pH 7.4. The hippocampi and frontal cortex were
dissected and transverse slices of 0.3 mm were obtained using a
McIlwain Tissue Chopper. Slices were then frozen at −20◦C (for
measurement of GFAP and S100B) or −80◦C (for measurement
GSH and NO), at most for 2 weeks.
ELISA for S100B
The S100B concentration was determined in the hippocampal
and cortical samples, in addition to serum and CSF from
offspring at PND 30 and PND 60. S100B levels were determined
by ELISA, as described previously (Leite et al., 2008). Briefly,
50 μL of sample plus 50 μL of Tris buffer were incubated
for 2 h on a microtiter plate, previously coated with anti-
S100B monoclonal antibody (SH-B1, from Sigma). Anti-S100
polyclonal antibody (from DAKO) was incubated for 30 min and
then peroxidase-conjugated anti-rabbit antibody was added for
a further 30 min. The color reaction with o-phenylenediamine
was measured at 492 nm. The standard S100B curve ranged from
0.002 to 1 ng/mL.
ELISA for GFAP
Enzyme-linked immunosorbent assay for GFAP was carried out
by coating the microtiter plate with 100 μL samples containing
20 ng of protein for 24 h at 4◦C. Incubation with a polyclonal
anti-GFAP from rabbit (GE Healthcare) for 1 h was followed
by incubation with a secondary antibody conjugated with
peroxidase for 1 h, at room temperature. A colorimetric reaction
with o-phenylenediamine was measured at 492 nm. The standard
human GFAP (from Calbiochem) curve ranged from 0.1 to
5 ng/mL.
Immunohistochemistry for GFAP and
NeuN
Rats were anesthetized using ketamine/xylazine and were
perfused through the left cardiac ventricle with 200 mL of saline
solution, followed by 200 mL of 4% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.4. The brains were removed and left
for post-fixation in the same fixative solution at 4◦C for 24 h.
Subsequently, the material was cryoprotected by immersing the
brain in 30% sucrose in phosphate buffer at 4◦C. The brains were
sectioned (50 μm) on a cryostat (Leitz). The sections were then
preincubated in 2% bovine serum albumin (BSA) in phosphate-
buffered saline (PBS) containing 0.4% Triton X-100 for 30 min
and incubated with polyclonal anti-GFAP from rabbit or -NeuN
from mouse, diluted 1:500 in 0.4% BSA in PBS-Triton X-100,
for 48 h at 40◦C. After washing several times, tissue sections
were incubated with a secondary antibody Alexa Fluor 488 (goat
anti-rabbit-IgG; green fluorescence) and Alexa Fluor 568 (goat
anti-mouse-IgG; red fluorescence) diluted 1:500 in PBS, at room
temperature for 2 h. Afterward, the sections were mounted on
slides with Fluor Save and covered with coverslips. Samples
were quantified according to (Centenaro et al., 2011). Briefly,
images were viewed with an Olympus microscope with a digital
camera and then transferred to a computer. Then, the GFAP
and NeuN immunoreactivity was evaluated by means of regional
semi-quantitative optical densitometry, using Image J Software
1.42q (Wayne Rasband, National Institutes of Health, USA). Five
images were analyzed in the stratum radiatum of the CA1 in the
hippocampus from each animal (four fields were analyzed per
section).
Glutathione Content Assay
Glutathione levels (nmol/mg protein) were measured, as
described previously (Anderson, 1985). Slices were homogenized
and assayed in 10 volumes of 100 mM sodium phosphate
buffer, pH 8.0, containing 5 mM EDTA and protein was
precipitated with 1.7% meta-phosphoric acid. Supernatant was
assayed with o-phthaldialdeyde (1 mg/mL methanol) at room
temperature for 15 min. Fluorescence was measured using
excitation and emission wavelengths of 350 and 420 nm,
respectively. A calibration curve was performed with standard
GSH solutions (0–500 μM).
Nitric Oxide (NO) Production
Nitric Oxide metabolites, NO3− (nitrate) and NO2− (nitrite)
were determined according to (Hu et al., 1996). Briefly,
homogenates from one hippocampus were mixed with 25%
trichloroacetic and centrifuged at 1,800 × g for 10 min. The
supernatant was immediately neutralized with 2 M potassium
bicarbonate. NO3− was reduced to NO2− by nitrate reductase.
The total NO2− in the supernatant was measured by a
colorimetric assay at 540 nm, based on the Griess reaction.
A standard curve was performed using sodium nitrate (0–
50 μM).
Protein Determination
Protein content was measured by Lowry’s method using BSA as
standard (Peterson, 1977).
Statistical Analysis
Parametric data are reported as means± standard error and were
analyzed by two-way ANOVA (followed by Bonferroni’s test).
Values of p< 0.05 were considered to be significant.
RESULTS
Prenatal LPS Treatment Increases S100B
in the Frontal Cortex and Hippocampus
of Offspring Rats
S100B content was measured in the frontal cortex and
hippocampus of juvenile (PND 30) and adult (PND 60) rats born
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from mothers exposed to LPS during pregnancy. Prenatal LPS
significantly changed only S100B levels in the frontal cortex of
male juvenile rats (p < 0.05). However, a significant effect of sex
on S100B levels in the frontal cortex [F(1,44)= 13,18; p= 0.0007]
and in the hippocampus [F(1,45) = 11,89; p= 0.001] in juveniles
rats was observed (Figures 1A,B).
In adult rats, a significant effect of prenatal LPS treatment
on S100B immunocontent was observed in the frontal cortex
[F(1,25) = 9,77; p = 0.005] and hippocampus [F(1,24) = 4,58;
p = 0.04], but no effect of sex was observed [F(1,25) = 3,23;
p = 0.08] and [F(1,24) = 3,57; p = 0.07] in these either of these
regions (Figures 1C,D).
Prenatal LPS Treatment Decreased
S100B Levels in the CSF of Young
Offspring Females
In juvenile rats, a significant interaction of (LPS treatment × sex)
was observed for the CSF levels of S100B [F(1,22) = 4,84;
p = 0.003]. Post hoc analysis revealed that S100B levels were
significantly lower in the females of the LPS group (p < 0.05),
when compared with the control group (Figure 2A). No
significant alterations were observed in the serum of juvenile
offspring (Figure 2B).
Prenatal LPS exposure did not significantly alter S100B levels
in the CSF or serum of adult offspring, however, an effect of sex
on the amount of S100B in the CSF was found [F(1,23) = 5,96;
p = 0.03] (Figures 2C,D).
GFAP Content is Altered in Offspring
Born to LPS-Treated Dams
A significant effect of prenatal LPS treatment [F(1,36) = 4,41;
p = 0.04] on GFAP immunocontent was observed in the frontal
cortex of juvenile offspring rats, but no influence of sex was
observed [F(1,36) = 0,82; p = 0.8] (Figure 3A). No effects of
LPS treatment [F(1,37) = 1,08; p = 0.30] or sex [F(1,37) = 0,68;
p = 0.41] were observed in the hippocampus of juvenile rats
(Figure 3B).
No changes were found in the frontal cortex of adult rats
(Figure 3C). However, significant effects of LPS treatment
[F(1,21)= 8,3; p= 0.008] and sex [F(1,21)= 5,94; p= 0.02] were
observed in the hippocampus of adult rats (Figure 3D).
Immunohistochemistry for GFAP and
NeuN in the CA1 Hippocampus of
LPS-Offspring Rats
In order to confirm the alterations in GFAP in the hippocampus
(measured by ELISA), we localized this protein in the CA1 region
using immunohistochemistry and also stained for the NeuN
protein in the neuronal population. Male and female rats born to
LPS-exposed damswere analyzed on PND30 and 60 (Figure 4A).
After quantification, significant effects of sex [F(1,10)= 18,66;
p = 0.002] and LPS treatment [F(1,10) = 30,62; p = 0.0002]
were observed on the GFAP immunocontent of the CA1
hippocampus in the offspring of PND 30 rats. There was also an
interaction effect between treatment and sex [F(1,10) = 10,51;
FIGURE 1 | Prenatal LPS treatment increases S100B in the frontal cortex and hippocampus of offspring rats. Cortical or hippocampal slices from PND 30
(A,B, respectively) and PND 60 Wistar rats prenatally exposed to LPS (C,D, respectively); S100B was measured by ELISA. Data are expressed as means ± standard
error (LPS group, N = 10; control group, N = 10), the measurements were performed in triplicate. aSignificant effect of prenatal treatment and bsignificant effect of
sex (Two-way ANOVA p < 0.05). ∗Significantly different from respective control (Bonferroni’s post hoc, p < 0.05).
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FIGURE 2 | Prenatal LPS treatment decreases S100B levels in the CSF of juvenile offspring females. CSF and serum from PND 30 (A,B, respectively) and
PND 60 Wistar rats prenatally exposed to LPS (C,D, respectively); S100B was measured by ELISA. Data are expressed as means ± standard error (LPS group,
N = 10; control group, N = 10), the measurements were performed in triplicate. bSignificant effect of sex (p < 0.05) and significant interaction prenatal
treatment × sex (Two-way ANOVA, p < 0.05). (A) ∗Significantly different from control (Two-way ANOVA followed by Bonferroni’s post hoc, p < 0.05).
FIGURE 3 | Glial fibrillary acidic protein content is altered in offspring born to LPS-treated dams. Cortical or hippocampal slices from PND 30 (A,B,
respectively) and PND 60 Wistar rats, prenatally exposed to LPS (C,D, respectively); GFAP was measured by ELISA. Data are expressed as means ± standard error
(LPS group, N = 10; control group, N = 10); the measurements were performed in triplicate. aSignificant effect of prenatal treatment and bsignificant effect of sex
(Two-way ANOVA, p < 0.05). ∗Significantly different from control (Bonferroni’s post hoc, p < 0.05).
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FIGURE 4 | Immunohistochemistry for GFAP and NeuN in the CA1 hippocampus of LPS-offspring rats. (A) Shows immunohistochemistry for GFAP (green)
and NeuN (red) in hipocampal slices of 30- and 60-day old Wistar rats prenatally exposed to LPS (males and females). GFAP and NeuN were then quantified in the
hippocampal slices of PND 30 (B,D, respectively) and PND 60 Wistar rats prenatally exposed to LPS (C,E, respectively). Data are expressed as means ± standard
error (LPS group, N = 5; control group, N = 5); the experiments were performed in triplicate. aSignificant effect of prenatal treatment; bsignificant effect of sex
(Two-way ANOVA, p < 0.05). ∗Significantly different from control (Bonferroni’s post hoc, p < 0.05). Scale bar = 10 mm.
p = 0.008] (Figure 4B). On PND 60, two-way ANOVA showed
a significant effect of sex (p = 0.0007), but there was no
effect of LPS treatment (p = 0.23 and 0.33, respectively)
(Figure 4C).
Prenatal LPS did not significantly change NeuN levels
in the hippocampus of juvenile or adult rats (Figures 4D,E
respectively); however, two-way ANOVA demonstrated a
significant effect of sex in both juvenile [F(1,12) = 33,27;
p< 0.0001] and adult [F(1,14) = 45,36; p< 0.0001] rats.
Offspring from LPS-Treated Dams
Demonstrate Alterations in
Oxidative/Nitrosative Stress
Glutathione content and NO production were used as parameters
to evaluate possible oxidative stress caused by LPS prenatal
exposure. Two-way ANOVA (treatment × sex) indicated no
significant effect of LPS treatment or sex in the frontal cortex
at PND 30 (Figure 5A). However, a significant effect of sex
[F(1,40) = 4,54; p = 0.03] was seen in the hippocampus at PND
30 (Figure 5B).
A significant effect of LPS treatment on GSH content was
observed in the frontal cortex at PND 60 [F(1,21) = 4,79;
p = 0.04] (Figure 5C); no effects were found in the hippocampus
at this age (Figure 5D).
The effect of LPS prenatal treatment on the content of NO
was observed in the frontal cortex of offspring rats at PND
30 [F(1,14) = 7,8; p < 0.014] (Figure 6A). Furthermore, a
significant effect of sex was observed in the hippocampus of
juvenile [F(1,12) = 33,27; p< 0.0001] (Figure 6B) and adult rats
[F(1,20) = 4,64; p = 0.043] (Figure 6C), where post hoc analysis
indicated an increase in NO in adult females.
DISCUSSION
Schizophrenia is believed to involve neurochemical, metabolic
activities and connectivity impairment between several brain
regions, such as the prefrontal cortex and hippocampus (Cui
et al., 2009; Ledoux et al., 2014). Increasing evidence suggests that
an imbalance of neurodegenerative and neuroprotective factors
may play a key role in this brain disorder. Of the factors that may
modulate the subtle balance between cell death and survival, a
role for cytokines has been consistently reported in SCZ (Mansur
et al., 2012). Previous studies indicate that astroglial dysfunction
could be an important element in SCZ pathology, as indicated
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FIGURE 5 | Glutathione content is dependent on sex and modulated by prenatal treatment with LPS. Cortical or hippocampal slices from PND 30
(A,B, respectively) and PND 60 Wistar rats prenatally exposed to LPS (C,D, respectively). Data are expressed as means ± standard error (LPS group, N = 10;
control group, N = 10), the experiments were performed in triplicate. Significant interaction prenatal treatment × sex (A); asignificant effect of prenatal treatment
(Two-way ANOVA, p < 0.05). ∗Significantly different from control (Bonferroni’s post hoc, p < 0.05).
by alterations in the markers GFAP and S100B (Fekkes et al.,
2009).
S100B is a calcium-binding protein secreted by astrocytes
into the synapse, where it is thought to participate in
synaptic plasticity (Donato et al., 2009) and glutamatergic
neurotransmission (Tramontina et al., 2006). The expression and
secretion of this protein is modulated by cytokines, suggesting
its involvement in the neuroinflammatory response (Schmitt
et al., 2007; de Souza et al., 2009). In addition, we observed that
cytokine-stimulated S100B secretion in astroglial cultures and
hippocampal slices can be prevented by antipsychotics (de Souza
et al., 2013). Herein, we showed that S100B has an age-dependent
pattern of expression, and that it is increased in the frontal cortex
and hippocampus of the LPS group at PND 60, when compared to
control rats, while juvenile male rats present an increase in S100B
levels only in the frontal cortex. It is important to mention that,
at this age, behavioral alterations such as disruption of prepulse
inhibition and deficient social interaction are associated with
the SCZ model induced by MIA (Smith et al., 2007; de Souza,
unpublished results).
As such, based on tissue S100B changes in the MIA model, we
may suggest that a higher astroglial sensitivity/reactivity occurs
in the frontal cortex of male offspring in response to prenatal
LPS exposure. Accordingly, we found an increase in GFAP in
the frontal cortex of the LPS group at PND 30, but not in the
hippocampus. Considering that S100B secretion is reduced by
elevation of glutamate levels in astrocyte cultures and brain slices
(Goncalves et al., 2002; Büyükuysal, 2005; Nardin et al., 2009), we
may speculate that this early increment in frontal cortex tissue of
offspring males is associated with elevated extracellular levels of
glutamate and glutamatergic hypofunction, commonly thought
to be involved in SCZ pathology (Javitt, 2010). In support, an
increment of glutamate levels has been reported in prefrontal
cortex of male offspring in other MIA models induced by LPS
(Connors et al., 2014) or polyinosinic:polycytidylic acid (Roenker
et al., 2012). Furthermore, we found a decrease in CSF levels of
S100B in females at PND 30 in the LPS group
These data are particularly interesting given the fact that
the first signs of SCZ generally occur at the beginning of
adulthood (Monji et al., 2009) and that an elevation of S100B
has been observed in patients during the first onset of SCZ
(Steiner et al., 2006). Elevations of serum S100B also have been
described in SCZ patients (Wiesmann et al., 1999; Lara et al.,
2001; Rothermundt et al., 2001), but no significant changes were
observed in serum S100B levels at the ages analyzed in this MIA
model. Furthermore, early CSF changes were not accompanied by
serum changes. It is important to emphasize that changes in CSF
S100B are not necessarily followed by changes in serum S100B
(Gonçalves et al., 2008; Guerra et al., 2011), even though serum
S100B, in SCZ,may be potentially modulated by peripheral S100B
sources (Gonçalves et al., 2010; Steiner et al., 2010).
However, while increased S100B levels in patients with SCZ
have been interpreted as a marker of structural damage or,
alternatively, as a sign of astroglial dysfunction (Wiesmann
et al., 1999; Rothermundt et al., 2001), the role of GFAP (a
classical marker of astrogliosis) in psychiatric disease remains
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FIGURE 6 | Nitric oxide content is dependent on sex. Cortical (A) and
hippocampal slices from PND 30 (B) and hippocampal slices from PND 60
Wistar rats prenatally exposed to LPS (C). Data are expressed as
means ± standard error (LPS group, N = 10; control group, N = 10);
experiments were performed in triplicate. bSignificant effect of sex (Two-way
ANOVA, p < 0.05). ∗Significantly different from control (Bonferroni’s post hoc,
p < 0.05).
controversial (Samuelsson et al., 2006; Hao et al., 2010). We
found a transitory increase of GFAP in the frontal cortex (but
not in the hippocampus) at PND 30 in offspring that had been
prenatally exposed to LPS, independent of sex. This hippocampal
increment of GFAP was observed only at PND 60, and the effect
was dependent on sex. Notably, when we looked specifically
at hippocampus CA1 using immunohistochemical staining for
GFAP, we found similar results at PND 60 when measuring
GFAP by ELISA. Conversely, in this hippocampal region, we
also observed astrogliosis at PND 30. Therefore, in spite of
methodological differences, taken together these results indicate
that astrogliosis in this LPS-induced MIA model is dependent on
sex, time and brain region.
In parallel to immunohistochemical studies for GFAP in
the CA1 hippocampus, we also stained for NeuN. We found
an ontogenetic difference in this protein’s levels in males and
females; however, no changes were observed at PND 30 or 60
after prenatal LPS exposure. In fact, no significant changes in the
number of neurons have been described in SZC patients (Heckers
and Konradi, 2002) or in MIA models of SCZ (Wolff and Bilkey,
2015). It is probable that SCZ does not occur as a consequence
of a reduction in neuron number, but due to alterations in
the interconnectivity between them (Selemon et al., 1995). Our
data reinforce the idea that alterations in astrocytes, glial cells
intimately related to synaptic plasticity, could contribute to the
abnormal connectivity of neurons.
In addition to glutamatergic communication,
oxidative/nitrosative stress has been associated with
SCZ pathology (Dadheech et al., 2008; Do et al., 2009;
Venkatasubramanian and Debnath, 2013). Astrocytes are a
heterogeneous group of cells involved in the production and
recycling of GSH (the main antioxidant molecule in brain tissue)
(Takuma et al., 2004), and also contribute to the production
of NO, which can cause nitrosative stress under certain
circumstances. However, nitrosative stress in the LPS-induced
MIA model has not been well characterized. We observed an
increase in NO in the hippocampus of female (not males) at
PND 60 following prenatal exposure to LPS. Unfortunately,
we were unable to measure NO metabolites in stored samples
from frontal cortex at this age. Surprisingly we observed an
increase in GSH in the LPS group, which was dependent on sex,
in the frontal cortex, but not in the hippocampus at PND 60.
The significance of these findings is unclear at moment, but the
increase in GSH could indicate a compensatory mechanism to
the oxidative stress that occurs in this model.
Some limitations of this study should be noted. Firstly,
MIA is a risk factor, not a model, as we have mentioned
throughout the text, for several developmental neuropsychiatric
disorders, including SCZ, autism and bipolar disorder. Secondly,
we have focused this study on astroglial cells; however, other
glial cells such as oligodendrocytes and microglia should also
be investigated as these also contribute to the behavioral
phenotypes of MIA observed at PND 60 (DF de Souza,
unpublished results). Finally, astrocytes, as mentioned, are a
heterogeneous group of cells, and the differences in levels of
S100B and GFAP observed in the different cerebral regions may
reflect this characteristic. Furthermore, numerous other specific
astroglial parameters such as glutamate transporters, glutamine
synthesis and GSH synthesis should be investigated in future
studies to amplify the understanding of astroglial activity in
MIA and SCZ pathology for diagnosis and even therapeutic
intervention.
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 December 2015 | Volume 9 | Article 489
de Souza et al. Astroglial Markers in SCZ Model
In summary, our results show that prenatal LPS challenge leads
to neurochemical abnormalities in astroglial markers during
postnatal life and these findings reinforce the hypothesis that
MIA may underlie SCZ pathology. The S100B protein exhibited
an age-dependent pattern of expression, being increased in
the frontal cortex and hippocampus of the MIA group at
PND 60, while at PND 30, male rats presented an increase
in S100B levels only in the frontal cortex. Considering that
S100B secretion is reduced by elevation of glutamate levels,
we may hypothesize that this early increment in frontal cortex
tissue of males is associated with elevated extracellular levels
of glutamate and glutamatergic hypofunction, an alteration
commonly associated with SCZ pathology. Accordingly, we
also found augmented GFAP expression in the frontal cortex
of the LPS group at PND 30, but not in the hippocampus.
Moreover, we found a decrease in CSF levels of S100B in
females at PND 30 in the LPS group, but not later on at
PND 60. Taken together, data indicate that astroglial changes
induced by MIA are dependent on sex and brain region, and
that such changes could reflect astroglial dysfunction. Such
dysfunction could help us, in part, to understand the abnormal
neuronal connectivity and developmental aspects of SCZ and
other psychiatric disorders.
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